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The  use  of anti-Ig  antibodies  to  stimulate  polyclonal  proliferation  through  Ig 
receptors expressed on the B cell membrane has been a  popular model for antigen- 
driven B cell activation (1-7). Initially it was proposed that anti-Ig-induced prolifer- 
ation  proceeded  independently  of T  cells  and  other  accessory  ceils,  as  vigorous 
depletion  of such  cell  types  failed  to  prevent  activation  (3,  8).  However,  certain 
features of anti-Ig-induced B cell activation challenged the view that the response was 
a  simple consequence of the interaction of anti-Ig and membrane Ig. In particular, 
the relationship between cell density and magnitude of the proliferative response was 
nonlinear  and  rapidly  declined  to  background  proliferation  levels at  cell  numbers 
below  105 per microtiter well (3, 6). Furthermore, the optimum doses of anti-Ig used 
in such studies far exceeded the amount required to saturate membrane Ig receptors 
and  induce  capping  of membrane  components.  Precise  delineation  of the  stimuli 
required  for anti-Ig-induced B  cell  activation requires  a  functional  assay in  which 
contaminating  accessory cells  potentially  capable of endogenous  factor production 
have  been  excluded.  To  this  end,  we  have  investigated  conditions  required  for 
polyclonal  activation of highly  purified  mouse B  lymphocytes cultured  at  low cell 
density (e.g., 5 ×  104 cells/well). Using such an assay, we have shown the role of a T 
cell-derived factor, designated B cell growth factor (BCGF), 1 in anti-IgM-induced B 
cell proliferation.  (9).  In this report we demonstrate that in the presence of optimum 
amounts ofBCGF, anti-IgM-induced proliferation of B cells cultured at lower densities 
(1-2  ×  104  cells/well)  is  enhanced  by  the  addition  of  a  second  soluble  factor. 
Biochemical analyses identify this second cofactor as the previously described  mon- 
okine interleukin  1 (IL-1). 
Materials and Methods 
Mice.  BALB/cJ mice were obtained from The Jackson Laboratory, Bar Harbor, ME, and 
used at 8-12 wk of age. CH3/HeJ mice, also obtained from The Jackson Laboratory, were used 
at 5-8 wk of age. 
* Supported in part by grant AI 17559 from the U. S. Public Health Service and grant PCM-8110370 
from the National Science Foundation, both to S. B. Mizel. 
1 Abbreviations  used  in  this  paper:  BCGF,  B  cell  growth  factor;  IEF,  isoelectricfocusing;  IL-1,  IL-2, 
interleukins  1 and 2;  PAGE, polyacrylamide gel electrophoresis;  PMA, phorbol myristate acetate; UV, 
ultraviolet. 
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Anti-IgM Antibodies.  Affinity-purified goat anti-mouse Ig specific  for/~ heavy chains (anti- 
IgM) was prepared as described previously (6). 
Culture Medium.  The culture medium used throughout was RPMI 1640 (Gibco Laboratories, 
Grand Island, NY) supplemented with 10% fetal calf serum (Reheis,  Kankakee, IL), penicillin 
(50/~g/ml), streptomycin (50/~g/ml), gentamycin (100/~g/ml), c-glutamine (200 mM), and 2- 
mercaptoethanol (5 ×  10  -s M)  (2ME). 
Growth Factor Preparations.  EL4 supernatant was produced by stimulating a cloned subline 
of EL4 thymoma with 10 ng/ml phorbol myristate acetate (PMA) as described elsewhere  (10). 
Cell-free  supernatants were  collected  after  48  h  and  depleted  of PMA  by  adsorption  on 
activated charcoal (11). For some experiments, BCGF was partially purified from EL4 super- 
natants by phenylsepharose chromatography or isoelectricfocusing (IEF) (12).  2 
Macrophages were stimulated to produce growth factors  by four different procedures. 
(a)  Stimulation of the cloned murine monocytic cell  line P388Da  with  1 #g/ml PMA, as 
described by Mizel et al. (13). Cell-free supernatants were collected after 5 d and depleted of 
PMA by two successive adsorptions on activated charcoal. For some experiments, the super- 
natants were concentrated ~200-fold by Amicon filtration, then fractionated by gel filtration 
on an AcA54 column as described previously (I0) to yield material of 10,000-20,000  mol wt. 
(b) Treatment of P388D1 cells with 2-4 rain ultraviolet (UV) irradiation (200-400 mJ/cm  2) 
using a bank of four Westinghouse FS20 bulbs) followed by their culture for 24 h in serum-free 
RPMI as described (Ansel, J., T. Luger, and I. Green, manuscript submitted for publication). 
(c)  A  superinduction protocol, designed to enhance IL-1  production by P388DI cells  for 
factor purification purposes.  This protocol involved co-culture of cells with protein and RNA 
synthesis inhibitors in addition to  PMA for  5  h, removal of these  agents by washing, then 
continued culture of the activated P388DI cells for a further 24 h (14). 
(d)  Stimulation of human acute monocytic leukemia cells with endotoxin and collection of 
cell-free supernatants 48 h later, as described by Lachman et al.  (I5). 
B  Cell Co-stimulator Assay.  Full details of this assay are given elsewhere  (9). Briefly, splenic 
B cells were purified by the procedure of Leibson et al.  (16), then cultured at densities rangin~ 
from 103 to 5 ×  105/well in 200/~1 medium in flat-bottomed 96-well microtiter plates (0.32 cm 
growth area). Some cultures contained affinity-purified  goat anti-IgM antibody at 5-10/~g/ml, 
and/or dilutions of the various growth factor preparations. Cultures were incubated at 37°C in 
a  humidified atmosphere of air containing  3 7.5% CO2 for  72 h.  The proliferative response of 
these cultures was determined by adding [ H]thymidine (1 /~Ci, 6.7 Ci/mmol; New England 
Nuclear, Boston, MA) for the last  12  16 h of culture and measuring [~H]thymidine incorpo- 
ration. 
Purification of IL-1.  Mouse and human IL-1 were purified according to previously published 
procedures  (14, 17,  18). Mouse IL-1  in super-induced P388Da  supernatants was  purified to 
apparent homogeneity using the following protocol: gel filtration chromatography, IEF, sulpho- 
propyl Sephadex cationic exchange chromatography, and tris glycinate polyacrylamide gel 
electrophoresis (PAGE). Human IL-1 was purified to high specific activity using the following 
procedures in sequence: hollow fiber diafiltration and ultrafihration, IEF, and tris glycinate 
PAGE (18, 19). Criteria for purity of the preparations yielded by these protocols are outlined 
elsewhere  (14, 17,  18). 
IL-1 Assay.  Mouse IL- 1 was measured as a co-mitogen with phytohemagglutinin  in a mouse 
thymocyte [3H]thymidine incorporation assay  (19). Human IL-1  was  measured as a  direct 
mitogen for mouse thymocytes in a [3H]thymidine incorporation assay (18). 
Results 
BCGF Dependence  of Anti-Ig-induced B  Cell Proliferation.  As has been shown previously 
(3,  6),  a  careful  analysis of the  relationship between B  cell  density and  anti-IgM- 
induced proliferation revealed a  sharp decline in response at cell numbers below 105 
per microtiter well (Fig.  1 A). This result strongly suggested that in addition to anti- 
IgM and the B  lymphocytes, other elements in the culture were limiting. We have 
2 Farrar, J., M. Howard, J. Fuller-Farrar, and W. E. Paul. Biochemical characterization of a murine B 
cell growth factor distinct from interleukin 2. Manuscript submitted for publication. A
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already shown (9)  that induced supernatants  from the mouse thymoma EL4 produce 
two  striking  effects  in  cultures  of anti-IgM  stimulated  B  cells:  (a)  a  shift  in  the 
antibody  concentration/response  relation  such  that  5  /~g/ml  anti-IgM  plus  EL4 
supernatant  induces  levels of proliferation  greater  than  those  induced  by 50/~g/ml 
anti-IgM alone, and  (b)  a  shift in the cell density/response  relation such that a  very 
substantial  response to 5-50/~g/ml anti-IgM can be obtained with as few as 5 ×  104 
B  cells/well.  Here  we  see  that  EL4  supernatant  enhanced  the  B  cell  proliferative 
response  at  cell  densities  ranging  from  5  ×  10a/well  to  5  ×  10S/well,  and  that 
essentially  identical  results  were  obtained  with  concentrations  of EL4 supernatant 
ranging between 5 and 30% indicating saturation conditions (Fig.  1 A). The B cell co- 
stimulating factor in EL4 supernatants has been examined in detail elsewhere (9, 12).2 
These  studies  show  that  the  factor,  designated  BCGF,  has  an  apparent  molecular 
weight by gel filtration of 18,000 and is clearly distinct  from interleukin  2  (IL-2) by 
gel filtration,  phenylsepharose chromatography, sodium  dodecyl sulfate-PAGE,  and 
IEF, as well as by cellular absorption studies.  BCGF partially purified by IEF caused 
the same maximal enhancement  of response to anti-IgM as did unfractionated  EL4 
supernatant  (Fig.  1B).  This  strongly suggests  that  the enhancing activity of EL4 is 
attributable  to its BCGF content. 
A Monokine Enhances BCGF-dependent Anti-IgM-induced B Cell Proliferation.  To explore 
the  possibility  of  a  macrophage-derived  factor  also  being  involved  in  anti-IgM- 
induced  B  cell  proliferation,  we selected  B  cell  co-stimulator  assay  conditions  that 
yielded low proliferative responses on a per cell basis to anti-IgM even in the presence 
of saturating amounts of EL4 supernatant,  i.e.,  1-2 ×  104 B cells/microtiter well plus 
10% EL4 supernatant  (see Fig.  1 A), and examined the effects of supplementing these 
cultures  with  induced  supernatants  from  the  cloned  murine  macrophage  cell  line 
P388D1. Others have shown that such supernatants are excellent sources of monokines 
such as IL-1  (13,  14,  20).  Unfractionated  PMA-induced  P388D1  supernatants  were 
found to profoundly inhibit  both BCGF-dependent  anti-IgM-induced and unstimu- 
lated background levels of B cell proliferation  (Table  I). As unfractionated  superna- 
tants  may contain both  inhibitors  and enhancing factors, we repeated  these experi- 
ments using fractionated components of induced P388D1 supernatants.  Thus, P388DI 
supernatants  were  fractionated  by  gel  filtration  using  a  calibrated  AcA54 column 
exactly as described elsewhere (10). Each column fraction was dialyzed against culture 
medium, and added at five serial dilutions to cultures containing  104 highly purified 
B  cells,  anti-IgM antibodies,  and a  saturating amount of the EL4 supernatant.  The 
results obtained  at  a  1:16 dilution  of column fractions revealed that  proliferation of 
TABLE I 
Effect of Unfractionated PMA-induced Macrophage Supernatants on B Cell 
Proliferation 
Macrophage factors  T cell factors 
cpm/5 X 104 B cells 
No anti-lgM  Plus Anti-IgM 
--  --  1,713 +- 267  2,133 _+ 301 
P388D~ supernatant  --  10 + 41  189 + 34 
--  EL4 supernatant  3,436 +  1,021  16,277  + 222 
P388Dt supernatant  EL4 supernatant  358 +- 27  482 +  103 
25% P388DI supernatant;  10% EL4 supernatant; 5/Lg/ml anti-IgM. HOWARD  ET  AL  1533 
such low numbers of B cells was markedly enhanced by the addition of macrophage- 
derived product(s) in the molecular weight range of 10-20,000 (Fig. 2). This material 
was not mitogenic for resting B cells, nor did it stimulate resting B cells in the presence 
of EL4 supernatant only. For convenience, the material was initially termed M 15 to 
signify its origin (i.e.,  macrophage) and approximate molecular weight (i.e., 15,000). 
A  pool was made of those fractions constituting the major peak of M15 activity (see 
hatched area of Fig.  2), and this pooled material was titrated under identical assay 
conditions. The results showed M15 to be (a)  inhibitory at high concentrations and 
(b) active over a wide concentration range below the inhibitory doses (Fig. 3 A). These 
findings have been reproduced using several different batches of M 15 prepared from 
separate  PMA-induced  P388D1  supernatants.  Similar  B  cell co-stimulator  activity 
was  found  in  supernatants  obtained  from  UV-irradiated  P388Da  cells  (Fig.  3B), 
thereby allaying concern regarding  the  potential  involvement of PMA  in  the  co- 
stimulatory activity of P388DI supernatants. 
The effect of M 15 on the cell density/response relationship of anti-IgM-induced B 
cell proliferation was tested using a  1:16 dilution of M 15, i.e., the optimal concentra- 
tion of this material (see Fig. 3 A). B cell proliferation was enhanced at all cell densities 
tested  (Fig.  1 C).  When  the  same  experiment was  performed in  the  presence of a 
saturating amount of the T  cell-derived lymphokine BCGF, a synergistic effect of the 
two factors was observed, particularly at low densities (Fig. 1 C). Identical results were 
obtained when a PMA-free source of M 15 (i.e., supernatant of UV-irradiated P388D1 
cells)  was  used  (Fig.  4A).  The  results  shown  in  Fig.  1  have  been  corrected  for 
proliferation obtained in the absence of anti-IgM antibodies, and thus represent anti- 
IgM-dependent  activation.  We emphasize that  both  M15  (see Figs.  2  and  3)  and 
43,500  18,800 12,384 
0  0,,/  100  110  120 
FRACTION NUMBER 
FIG.  2.  Gel filtration analysis orB cell co-stimulator activity in PMA-induced P388Da supernatant. 
Fractions collected from an AcA54 column were dialysed against culture medium, then added at a 
final  concentration  of  1:16  to  cultures  containing  104  purified  B  cells  per  well  and  10%  EL4 
supernatant with or without anti-lgM antibodies (5/xg/ml). Proliferation was assessed at day 2.5 by 
[SH]thymidine uptake. The calibrating molecular weight markers were ovalbumin (43,500), myo- 
globin (18,800), and cytochrome c (12,384). All results represent duplicate cultures. 3 
× 
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-A 
1/2  1/8  1/32  1/121B 1/512  0 
SUPT, DILUTION 
1/-/2  I  I  I  I  I  I  I  I  ,,~ 
1/8  1/32  1/128  1/512  0 
SUPT, DILUTION 
5- B 
1534 
Fto.  3.  B cell co-stimulator activity in (A) a  I0,000-20,000-moi wt pool made from PMA-induced 
P388Dt supernatant (equivalent to hatched area of Fig. 2), or (B) supernatant collected from UV- 
irradia(ed P388Dt cells (refer to Materials and Methods). Supernatants were added at final dilutions 
of from  1/2  to  1/512  to cultures containing  104 purified B  cells and  10%  EL4 supernatant, with 
(0)  or without  (O)  anti-IgM antibodies  (5 p.g/ml).  Proliferation  was assessed at  day 2.5 by [aH]- 
thymidine uptake. Results repesent duplicate cultures. 
+2ME 
105 '-+  BCGF+  ~  IC~ 
d  d 
103  103 
-2ME 
+ B CG~~,~ 
~  NO GF 
'11~  -  I  I  I  I  .-  J  10;  -  I  I  I  I  I 
104  2x104 5x104 1125  5×105  1134  2x10  =  5x104 105  5x105 
B CELLS/WELL  B CELLS/WELL 
Fm~  4.  Proliferative response of purified B cells cultured with anti-lgM (5/~g/mt)  together with 
various co-factors either in culture medium containing 2 X  10  -~ M  2ME or in 2ME-free medium. 
Co-factor supplements were: (a) phenyl Sepharose-parified BCGF, prepared as in reference 12 (also 
footnote 2) and added at a  l:50 final dilution found to he saturating for co-stimulator activity at the 
B cell density of 5 X 10*/well; (b) supernatant collected from UV-irradiated P388D1 cells and added 
at a final dilution of 1:4 (designated MI5);  (c)  medium only (NO GF);  (d) a mixture of (a) and (b). 
Other assay conditions were as in Fig.  1. 
BCGF  (9)  produce  little  proliferation  in  the  absence  of anti-IgM  antibodies.  In 
summary,  these  data  strongly  imply  roles  for both  BCGF and  MI5  in  anti-IgM- 
induced B cell proliferation. 
Absolute Need for M15 in 2ME-free  Cultures.  M15-mediated enhancement of anti-Ig 
induced BCGF-dependent B cell proliferation was highly reproducible from e×peri- 
ment to experiment. However, the magnitude of its effect was often relatively small 
(two- to fourfold), making it difficult to clearly determine whether BCGF and M15 HOWARD ET AL.  1535 
acted synergistically or additively. This problem was resolved by taking advantage of 
the observation that  B cell proliferation experiments performed in culture medium 
lacking 2ME show an exaggerated need for exogenously added M15. Fig. 4 shows B 
cell proliferative responses to anti-IgM plus cofactors in medium containing or lacking 
2ME. While the maximum proliferation levels obtained in the presence of anti-IgM, 
BCGF, and  M15  were the same in both media, a  significant response to anti-IgM 
alone, i.e., in the absence of exogenously added BCGF and M15, was only obtained 
when  B  cells were cultured  in  2ME-containing medium;  in  the absence of 2ME  a 
response to anti-IgM and BCGF was only observed at 5 ×  105 cells/well, the highest 
cell density tested (Fig. 4 B). In cultures lacking 2ME, M 15 has a marked costimulatory 
effect at  all  densities.  These  data  prompt  speculation  regarding  the  possibility  of 
endogenous 2ME-mediated M15 production by residual macrophages and/or B cells 
in our standard BCGF co-stimulator assay. The striking M 15-dependent enhancement 
of B cell proliferation observed in 2ME-free cultures clearly establishes the synergy 
between  BCGF  and  M15,  suggesting  that  both  co-factors  operate  on  the  same 
population of B cells. 
Identification ofM15as IL-1.  In terms of approximate molecular weight and cellular 
origin,  M15  resembles  the previously described monokine IL-1. To investigate the 
possible  identity of these two factors, we  tested murine  and  human  IL-1, purified 
according  to  previously  established  procedures,  for  M15  activity,  i.e.,  ability  to 
enhance the proliferation of low numbers of purified B cells cultured with anti-IgM 
and saturating doses of EL4 supernatant. 
Murine IL-1  can  be obtained in large quantities  by a  superinduction procedure 
involving pre-cuhure of P388Da cells with PMA in the presence of protein and RNA 
inhibitors (14). Mizel and Mizel (14) have purified the IL-1 in this crude supernatant 
to apparent homogeneity by a  modification of a  previously published fractionation 
scheme involving gel filtration, IEF, sulpho-propyl Sephadex cationic exchange, and 
tris  glycinate  PAGE.  As  expected,  the  15,000-tool  wt  material  obtained  by  gel 
filtration  of supernatant  from  superinduced  P388D1  cells  showed  excellent  M15 
activity when added to cultures of highly purified B cells, anti-IgM, and saturating 
amounts of EL4 supernatant (data not shown). The 15,000-tool wt material was then 
further purified by IEF, sulpho-propyl Sephadex cationic exchange, and tris glycinate 
PAGE.  Fractions  from the  tris  glycinate gel  were  dialyzed, then  assayed  for M15 
activity using the B cell co-stimulating assay described above and  for IL-1 activity 
using the conventional mouse thymocyte proliferation assay. The two activity profiles 
were indistinguishable  (Fig. 5), indicating either that M15 is IL-1 or that  there is a 
great biochemical similarity between them. 
Human and murine IL-1  are functionally interchangeable in a  variety of T  cell 
assays (S. B. Mizel, unpublished observations). Thus, to further assess the relationship 
between M15 and IL-1, we tested purified human IL-1 for M15 activity. Human IL- 
l can be obtained in large quantities by incubating freshly collected acute monocytic 
leukemia cells with endotoxin (15). Lachman et al. (17) have purified the IL-1 in this 
crude  supernatant  to  high  specific  activity  by  sequential  fractionation  involving 
hollow fiber filtration, IEF, and tris glycinate PAGE (17,  18). This combination of 
procedures generally yields a preparation that is free of endotoxin, as assessed by the 
Limulus  assay  (L.  Lachman,  unpublished  data).  The  10-50,000-mol  wt  material 
obtained by hollow fiber filtration was subjected to IEF, and dialyzed fractions were 20000 
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duced  P388D1  supernatants was purified to apparent  homogeneity as described in text. Dialyzed 
fractions obtained from  the  final tris glycinate gel electrophoresis were added at several dilutions 
ranging from  1/8 to  1/2048 to cultures of 2  X  104 B  ceils, 10% EL4 supernatant, and anti-IgM (5 
~g/ml)  (O),  or  to  cultures of  1.5  X  10  ~ mouse thymocytes and  phytohemagglutinin  (0).  In both 
cases,  proliferation was  assessed at  day  2.5  by  [aH]thymidine  uptake.  For  each  fraction,  relative 
units of activity represent the inverse of the dilution that produced 50% of the maximum proliferation 
obtained in that assay. All results represent means of duplicate cultures. 
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(0). In both cases, proliferation was assessed at day 2.5 by [aH]thymidine uptake. Units of B cell co- 
stimulator activity were calculated as outlined in Fig. 5. All results represent duplicate cultures. 
assayed  for M15  and IL-1  activity.  The two activities  had a  concordant  distribution 
with a  peak in activity  in the pI  7.0 fractions  (Fig.  6). The pI 6.8-7.2  fractions  from 
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Fro.  7.  B cell co-stimulating activity of purified human IL-1. Two separate preparations (0, I D of 
human IL-1  from endotoxin-stimulated monocytic leukemia cells were  purified  to  high specific 
activity as described  in  text.  Each  preparation  was added  at  the various dilutions indicated  to 
cultures of 2 ×  10  4 B cells,  10% EL4 supernatant with or without anti-IgM at 5 #g/ml (B cell co- 
stimulator assay), or mouse thymocytes (T cell co-stimulator assay). Proliferation  was assessed at 
day 2.5 by [~H]thymidine uptake. Results represent means of duplicate cultures. 
a  tris glycinate polyacrylamide gel.  In  two separate experiments, the  fraction that 
contained IL-1 activity was shown to be also rich in M15 activity (Fig. 7). 
The biochemical results correlating B cell and thymocyte co-stimulating activities 
from two separate sources of IL-1 provide strong evidence that M 15 is the monokine 
IL-1 and thus that IL-1, together with BCGF, plays a key role in the stimulation of 
anti-IgM treated B cells to enter the S phase of the cell cycle. 
Discussion 
We report here conditions  for polyclonal activation of small  numbers  of highly 
purified mouse  B  lymphocytes. Three stimuli  are  required  for induction  of DNA 
synthesis by the particular subset of small B lymphocytes investigated: one delivered 
by antibodies specific for the IgM receptor expressed on the B cell membrane;  one 
delivered by the T  cell-derived factor BCGF; and one delivered by the 15,000-mol wt 
macrophage-derived factor IL-1. BCGF is a newly described lymphokine discussed in 
detail elsewhere (9, 12). 2 Identification of the monokine involved in this process as IL- 
l  is based on correlation of B cell and T  cell co-stimulating activities following an 
extensive series of  biochemical purification procedures. Indeed, the purest preparations 
of murine and human  IL-1 currently available show excellent B cell co-stimulating 
activity in our assay systems. We do not believe that the B cell co-stimulatory activity 
contained in IL-l-containing supernatants  can be attributed to the PMA generally 
used for IL- 1 induction for several reasons: (a) PMA-free IL- 1-containing supernatants 
obtained from UV-irradiated  P388Da  cells contain the B  cell-costimulant;  (b)  The 
IL-1-rich supernatant obtained by the superinduction protocol is produced by expos- 
ing P388D1 cells to PMA for 5 h, extensively washing the cells, culturing them for 24 
additional h and collecting that supernatant. No PMA can be detected in the purified 1538  INTERLEUKIN 1 AND B CELL RESPONSIVENESS 
preparation,  as assessed  by the inclusion of isotopically labeled  PMA in test  batches 
of supernatant  (Mizel, unpublished  data);  (c) The human IL-l-containing superna- 
tant  is induced by endotoxin rather than by PMA; and  (d) The B cell co-stimulant 
resided in IL-1 purified to apparent  homogeneity. We wish to emphasize that BCGF 
and  IL-1  do  not  appear  to  be  mitogenic  for  resting  B  cells.  Furthermore,  BCGF 
derived from an H-2  b line (EL4) functions on BALB/c (H-2  d) B cells and IL-1 derived 
from  an  H-2  a  line  (P388D1)  functions  on  CBA  (H-2  k)  B  cells  (unpublished  data). 
Thus, these factors act on anti-IgM-activated B cells in a  non-antigen-specific, non- 
H-2-restricted  manner.  The  fact  that  BCGF  and  IL-1  co-stimulatory  effects  are 
synergistic rather  than  additive  suggests the two  factors operate on the same B  cell 
subset.  We show elsewhere that BCGF does not lead to the appearance of antibody- 
forming cells, but  is nevertheless  an essential component in both an antigen-induced 
antibody-forming cell response  (9)  and in the induction of cells with cytoplasmic Ig 
in  response  to  anti-lgM. 3  Preliminary  experiments  suggest  a  similar  role  for  IL-1 
(unpublished  observations).  The involvement of accessory cells in anti-IgM-induced 
B cell proliferation has previously been a matter of controversy; however, involvement 
of either macrophages or T  cells has been reported by some laboratories  (28-30). We 
suggest  that  failure  to obseve the  need  for one or both  cell  types reflects  the use  of 
assay conditions  in which small  numbers  of one or both  accessory cells  are  present 
with  consequent  endogenous  factor production.  Our own experiments  show a  need 
for exogenous BCGF and  IL-1 only at  low cell  densities,  despite  the rigorous B  cell 
purification procedure we have used. Thus it would appear that very small numbers 
of accessory ceils can provide B cell stimulatory co-factors. 
Three  major models  to explain  antigen-specific  B  cell  activation  have previously 
been proposed: (a) activation occurs as a result of the binding of antigen to membrane 
Ig (8, 31); (b) activation occurs via an unrelated nonspecific receptor, with membrane 
Ig serving to specifically focus molecules capable of binding to this receptor (32); and 
(c) activation requires both a signal resulting from the binding of the Ig receptor and 
a  signal delivered by an interaction at another antigen-nonspecific receptor on the B 
cell membrane (33). In this study, we arrive at the novel conclusion that IgM-specific 
induction  of B  cell  proliferation  requires  three  stimuli:  one specific  for the  antigen 
receptor, and two antigen-nonspecific stimuli. Preliminary kinetic analyses investigat- 
ing the  relative  roles  of BCGF and  IL-1  in  the  B  cell  cycle suggest  the  two  factors 
function independently, with BCGF operating on Go or early G1 cells and IL-1 acting 
at some later point of G1 (34; M. Howard and E. Rabin, unpublished data).  It seems 
likely  that  the  time  of action  of the  co-stimulant  correlates  with  that  time  that 
receptors for them are expressed on the B cell surface, just as T  cell sensitivity to IL- 
2  appears  to correlate with the expression  of receptors  for IL-2 on T  cells that  have 
been  stimulated  with  lectins  or  antigens  (35-37).  However,  no  direct  evidence  for 
receptors for BCGF or IL-1 on activated mouse B cells has yet been obtained. 
This report  establishes  a  role for IL-1 in stimulation  of B cells.  While others have 
previously proposed roles for IL-1 in B cell responses  (38-44), such experiments were 
conducted using less pure  B  cell  populations  cultured  at  high cell  density and  thus 
failed  to distinguish  a  direct  action  on  B  cells  vs.  secondary  actions  via  other  cell 
a Nakanishi, K., M. Howard, A. Muraguchi, J. Farrar, K. Takatsu, T. Hamaoka, and W. E. Paul. 1983. 
Soluble factors involved in B cell differentiation: identification of two distinct T cell replacing factors 
(TRF).J. Immunol. In press. HOWARD ET  AL.  1539 
types. A  particular problem in  this respect  is  that  IL-1 appears responsible for the 
generation of at least some T  cell-derived lymphokines, e.g., IL-2 (22-25) and colony- 
stimulating factor (26). With the recent identification of several distinct B cell-specific 
lymphokines  a (9,  16, 27, 30, 45-48), one could certainly envisage IL-1-mediated factor 
cascades in many biological assays for B cell function. While such objections may be 
leveled at our experiments, we offer the following considerations:  (a)  We have used 
very highly purified B  cells cultured  at  low cell densities,  thus  greatly reducing the 
possibility of accessory cell contamination.  (b) We show elsewhere (34) that IL-1 may 
be added quite late in the B cell cycle, thus providing little opportunity for a  factor 
cascade to develop. (c) Other T  cell-derived B cell-specific lymphokines, e.g., BCGF, 
and the T  cell-replacing factors from the EL4 (EL-TRF) and the B 15K 12 (B 15-TRF) 
T  cell lines  a fail to replace the need for IL-1 (unpublished data). Nevertheless, ultimate 
proof of IL-1 acting directly on B cells will await reagents capable of demonstrating 
its specific binding to cellular receptors. The observation that IL- 1 dependency of B 
cell proliferation is heightened by omitting 2ME from the culture medium is reminis- 
cent of the earlier studies of Mongini et al.  (28), who demonstrated an accessory cell 
requirement  for anti-IgM  induced  B  cell  proliferation  under  2ME-free conditions. 
2ME has been used extensively as an additive to culture medium in a variety of tissue 
culture  systems  to  either  augment  the  magnitude  or  facilitate  observation  of the 
particular phenomenon  under study.  While  2ME  has been directly implicated as a 
lymphocyte mitogen and  polyclonal  activator  (49,  50),  our experiments suggest  an 
alternative mode of action, namely as a  stimulant  that  induces  IL-1 production  by 
residual macrophages and/or B ceils. 
We wish to emphasize that the conclusions reached from these studies reflect the 
activation  requirements  of the subset  of B  cells that  can  proliferate in  response  to 
anti-IgM antibodies. This subset has recently been quantitated  as comprising ~50% 
of normal splenic B cells (21).  Such cells are absent from xid mice and appear to be 
members of the Lyb-5  + population of normal B cells. Thus, our data do not exclude 
the existence of a  separate subset of B  cells which  interact  with T  cells in  an H-2- 
restricted manner, as demonstrated by others (51-53).  Finally, it is difficult to relate 
the findings of this investigation to those recently obtained in other laboratories using 
elegant single-cell assays for B cell growth (54-56). As such studies have not used anti- 
IgM antibodies as the primary activant, different B cell subsets may be under study. 
Furthermore, the increased sensitivity of single-cell assays over those described in this 
report may allow detection of trace amounts of growth factors in cell supernatants or 
indeed in the fetal calf serum contained in culture medium itself, producing results in 
apparent conflict with ours. Attempts to resolve some of these issues are in progress. 
Summary 
In this report we describe conditions for polyclonal activation of small numbers of 
highly  purified  mouse  B  lymphocytes. Three signals  are required  for induction  of 
DNA synthesis by the particular subset of small B lymphocytes investigated: a signal 
delivered by antibodies  specific for the IgM receptor expressed on the B  cell mem- 
brane;  a  signal delivered by a  T  cell-derived factor (B cell growth  factor [BCGF]); 
and  a  signal  delivered  by the  macrophage-derived factor interleukin  1  (IL-1). The 
conclusion  that  IL-1  has B  cell co-stimulator activity is  based on  the  findings  that 
highly purified preparations of mouse and human  IL-1  have the capacity to cause 1540  INTERLEUKIN  1 AND  B CELL  RESPONSIVENESS 
proliferation  in  B  cells  treated  with  anti-IgM  and  BCGF.  Such  cultures  show  an 
absolute dependence on exogenously added IL-1 when 2-mercaptoethanol is omitted 
from  the  medium.  BCGF  and  IL-1  each  act  in  a  non-antigen-specific,  non-H-2- 
restricted,  synergistic manner.  Their  requirement  is not  observed when  B  cells are 
cultured  at  high  density,  presumably  reflecting  accessory  cell  contamination  and 
endogenous factor production under these conditions. The B  cell activation induced 
by these three signals is restricted to proliferation without the production of antibody- 
forming cells. 
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